Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Other financing activities (2021 - 2023)

Werewolf Therapeutics (HOWL) has disclosed Other financing activities for 3 consecutive years, with -$90000.0 as the latest value for Q2 2023.

  • On a quarterly basis, Other financing activities fell 137.66% to -$90000.0 in Q2 2023 year-over-year; TTM through Sep 2024 was -$90000.0, a 64.43% increase, with the full-year FY2024 number at $673000.0, changed N/A from a year prior.
  • Other financing activities was -$90000.0 for Q2 2023 at Werewolf Therapeutics, down from $90000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.5 million in Q2 2021 to a low of -$2.4 million in Q4 2021.
  • A 3-year average of $9777.8 and a median of $102000.0 in 2022 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: soared 89.41% in 2022, then crashed 137.66% in 2023.
  • Werewolf Therapeutics' Other financing activities stood at -$2.4 million in 2021, then skyrocketed by 89.41% to -$253000.0 in 2022, then soared by 64.43% to -$90000.0 in 2023.
  • Per Business Quant, the three most recent readings for HOWL's Other financing activities are -$90000.0 (Q2 2023), $90000.0 (Q1 2023), and -$253000.0 (Q4 2022).